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Abstract
Background: Dysvascular partial foot amputation (PFA) is a common sequel to advanced peripheral vascular
disease. Helping inform difficult discussions between patients and practitioners about the level of PFA, or the
decision to have a transtibial amputation (TTA) as an alternative, requires an understanding of the current research
evidence on a wide range of topics including wound healing, reamputation, quality of life, mobility, functional
ability, participation, pain and psychosocial outcomes, and mortality. The aim of this review was to describe a
comprehensive range of outcomes of dysvascular PFA and compare these between levels of PFA and TTA.
Methods: The review protocol was registered in PROSPERO (CRD42015029186). A systematic search of the literature
was conducted using MEDLINE, EMBASE, psychINFO, AMED, CINAHL, ProQuest Nursing and Allied Health, and Web
of Science. These databases were searched using MeSH terms and keywords relating to different amputation levels
and outcomes of interest. Peer reviewed studies of original research—irrespective of the study design—were
included if published in English between 1 January 2000, and 31 December 2015, and included discrete cohort(s)
with dysvascular PFA or PFA and TTA. Outcomes of interest were rate of wound healing and complications, rate of
ipsilateral reamputation, quality of life, functional ability, mobility, pain (i.e., residual limb or phantom pain),
psychosocial outcomes (i.e., depression, anxiety, body image and self-esteem), participation, and mortality rate.
Included studies were independently appraised by two reviewers. The McMaster Critical Review Forms were used
to assess methodological quality and identify sources of bias. Data were extracted based on the Cochrane
Consumers and Communication Review Group’s data extraction template by a primary reviewer and checked for
accuracy and clarity by a second reviewer. Findings are reported as narrative summaries given the heterogeneity of
the literature, except for mortality and ipsilateral reamputation where data allowed for proportional meta-analyses.
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Results: Twenty-nine unique articles were included in the review, acknowledging that some studies reported
multiple outcomes. Eighteen studies reported all-cause proportionate mortality. A smaller number of studies
reported outcomes related to functional ability (two), mobility (four), quality of life (three), ipsilateral reamputation
(six) as well as wound healing and complications (four). No studies related to pain, participation or psychosocial
outcomes met the inclusion criteria. Subjects were typically older and male and had diabetes among other
comorbidities. More detailed information about the cohorts such as race or sociodemographic factors were
reported in an ad hoc manner. Common sources of bias included contamination, co-intervention, or lack of
operational definition for some outcomes (e.g., wound healing) as illustrative examples.
Conclusions: Aside from mortality, there was limited evidence regarding outcomes of dysvascular PFA, particularly
how outcomes differ between levels of PFA and TTA. Acknowledging that there is considerable uncertainty given
the small body of literature on many topics where the risk of bias is high, the available evidence suggests that a
large proportion of people with PFA experience delayed wound healing and ipsilateral reamputation. People with
TTA have increased risk of mortality compared to those with PFA, which may reflect that those considered suitable
candidates for TTA have more advanced systemic disease that also increases the risk of dying. Mobility and quality
of life may be similar in people with PFA and TTA.
Systematic review registration: CRD42015029186
Keywords: Amputation, Partial foot, Mobility, Participation, Function, Quality of life, Mortality, Reamputation,
Psychosocial, Pain
Background
Dysvascular lower limb amputation is a common sequel
to advanced peripheral vascular disease resulting in a
wide range of adverse health outcomes (e.g., impaired
mobility, depression) that often lead to significant dis-
ability and reduced quality of life (QoL) [1, 2]. Hence, it
is not surprising that the decision to proceed with am-
putation, even so-called minor or partial foot amputation
(PFA), is a difficult one.
Helping people make well-informed decisions about
PFA has become increasingly important given the shift in
types of lower limb amputation performed [3–7]. The inci-
dence of transtibial amputation (TTA) has declined stead-
ily since about the year 2000 [3, 8–11], and there is some
evidence that PFA has increased proportionately [3, 6, 10].
The shift to more distal amputation may be seen as
a significant improvement given the assumption that
more distal amputation results in better mobility [12],
improved QoL [13–15], and lower mortality [16–18].
However, PFA has been associated with low rates of
healing and complications [13, 14, 19–22] that often
lead to ipsilateral reamputation [20, 23–28]. The low
rates of healing and high rates of reamputation in
people with PFA are disproportionate given that most
TTAs heal and only a small proportion require ipsi-
lateral reamputation [24, 28–30].
Some authors [31, 32] have challenged the belief that
the high rates of complications and reamputation associ-
ated with PFA are worth the benefits, particularly given
that key outcomes such as mobility [33, 34] and QoL
[35–38] appear to be comparable in people with PFA
and TTA. However, closer scrutiny of the evidence is ne-
cessary [39–41] given that much of the literature has fo-
cused on people with amputations through the midfoot
(e.g., transmetatarsal amputation, TMA) and outcomes
may be better for people with toe amputations [39, 40].
Similarly, very high rates of wound healing have been re-
ported in some studies of people with PFA—comparable
to those for people with TTA—but it is unclear what
most influenced the outcomes [19, 42] or whether these
outcomes are typical of the broader body of literature.
While research seems to have focused on outcomes
related to surgery, mortality, QoL, and mobility, it is
also important that decisions about PFA are informed
by an understanding of the outcomes related to par-
ticipation, functional ability, pain, and psychosocial
considerations including depression, anxiety, body
image, and self-esteem.
A systematic review describing a comprehensive range of
outcomes following PFA would help provide the evidence
needed for people to make well-informed decisions about
the level of PFA and how this compares to TTA, par-
ticularly if the results could be used to create shared
decision-making resources designed to facilitate and inform
discussions between clinicians and patients [43]. Hence,
the aims of this systematic review were to:
(1)Describe the outcomes of dysvascular PFA with
reference to wound healing and complications,
ipsilateral reamputation, QoL, functional ability,
mobility, pain, psychosocial outcomes, participation,
and rate of mortality.
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(2)Compare these the same outcomes between levels of
PFA and TTA.
Methods
A detailed protocol for this systematic review was regis-
tered in PROSPERO (CRD42015029186) and published
prior to conduct of the review [44]; hence, a summary of
the method has been reported here. The review was re-
ported in accordance with the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines [45] including a copy of the PRISMA check-
list (Additional file 1).
Search strategy
A systematic search of the literature was conducted
using MEDLINE, EMBASE, psychINFO, AMED,
CINAHL, ProQuest Nursing and Allied Health, and
Web of Science. A list of search terms related to the
population (e.g., PFA) and outcomes of interest (e.g.,
QoL), as well as their synonyms and acronyms, were
used in conjunction with wildcards and Boolean opera-
tors as part of a title, abstract, and keyword search [44].
Each search strategy was rigorously developed, tested,
and refined by comparing the precision and comprehen-
siveness of the yield to a bank of known articles on each
topic [44].
All searches were restricted to the English language
given that such restriction does not seem to alter the out-
come of systematic reviews and meta-analyses [46, 47].
Searches were also restricted to publications since 1
January 2000, given that changes in treatment practices
(e.g., common place use of revascularization prior to, or in
conjunction with, amputation) have affected the outcomes
since this time as evidenced by changes in the relative risk
of amputation [8, 9, 11].
In keeping with the PRISMA guidelines [45], an illus-
trative search has been presented for one database
(Table 1).
For articles that met the inclusion criteria, reference
lists were hand searched to ensure that relevant publica-
tions were not overlooked. A forward-citation search
was conducted using Google Scholar to identify litera-
ture published since 1 January 2014, (e.g., early on-line
versions of articles) that had not yet been indexed in
traditional databases [48–50].
Data management
Results from each database search were exported into a
shared EndNote X7.2.1 library (Thomson Reuters Inc.,
Philadelphia, PA, USA.) and duplicate records deleted
[44]. Full-text copies of articles were retrieved and linked
to the relevant EndNote record. Bibliographic informa-
tion for each reference were exported into an Excel 2013
(Microsoft Corporation Inc., North Ryde, Sydney,
Australia) spreadsheet and columns added to record de-
tails about exclusion and full-text retrievals. The same
spreadsheet was expanded for data extraction and to
record details of the critical appraisal [44].
Table 1 Example search for the CINAHL database to identify quality of-life literature for people with dysvascular partial foot and
transtibial amputation
Search Field code Search term(s)
1. MH “Amputation”
2. MH “Amputees”
3. TI,AB,SU (amput* AND (major OR lowerlimb* OR “lower limb”* OR “lower extremit*” OR “limb loss” OR LEA OR LLA))
4. TI,AB,SU (amput* AND (transtibial OR “trans tibial” OR belowknee OR “below knee” OR (below W2 knee) OR TTA OR BKA))
5. TI,AB,SU (amput* AND (minor OR “partial foot” OR Chopart* OR Lisfranc* OR tarsometatarsal OR transmetatarsal OR midtarsal
OR “mid tarsal” OR midfoot OR “midfoot” OR ray OR phalangeal OR metatarsophalangeal OR toe* OR transtarsal
OR “trans tarsal” OR TMT OR TMA OR MTP OR PFA))
6. 1 OR 2 OR 3 OR 4 OR 5
7. TI,AB,SU SF 36 OR SF36 OR “Medical Outcome* Study Short Form*” OR “Medical Outcome* Study Short-Form*” OR “MOS SF 36”
OR “MOS SF36” OR “Sickness Impact Profile*” OR “SIP” ((“Trinity Amputation and Prosthe* Experience”) W1 (Survey OR Scale*))
OR TAPES OR “Prosthe* Evaluation Questionnaire” OR PEQ OR “WHO QOL BREF” OR “WHO QOLBREF” OR “WHOQOLBREF” OR
((WHO OR “World Health Organi#ation”) W1 (“Quality of Life BREF” OR “Quality of Life Scale”)) OR “RAND36” OR “RAND 36” OR
“Orthotic*and Prosthetic* User* Survey” OR OPUS OR ((“Health Related”) W1 “Quality of Life”) OR HRQOL OR “Life Satisfaction
Questionnaire* 9” OR “LiSat 9” OR “Satisfaction With Life Scale” OR SWLS OR “Quality of Well Being” OR QWB* OR “Quality of
Life Index” OR QLI OR “EuroQOL*” OR “Euro QOL” OR EQ5D OR “EQ 5D” OR “Assessment of Quality of Life” OR AQoL OR
(Orthotic* W2 “prosthetic* user* survey”) OR “Attitude to Artificial Limb* Questionnaire” OR AALQ
8 6 AND 7
9. Limit 8 to English language
10. Limit 9 to publication date: 01.01.2000 to 31.12.2015
11. Limit 10 to peer reviewed, academic journals
Field codes: MH Exact major and minor subject headings (MeSH, National Library of Medicine Medical Subject Headings), TI Title, AB Abstract, SU Subject. Asterisk
denotes wildcards used to capture truncation or variation of the search terms
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Selection process
The following criteria were used to determine inclusion:
1. Peer reviewed studies of original research,
irrespective of the study design
2. English language
3. Published between 1 January 2000 and 31 December
2015
4. Discrete cohort(s) with dysvascular PFA, irrespective
of the level of PFA (aim 1) or PFA and TTA (aim 2)
5. Measured an outcome of interest—rate of wound
healing and complications (e.g., dehiscence), rate of
ipsilateral reamputation, QoL, functional ability,
mobility, pain (i.e., residual limb or phantom pain),
psychosocial outcomes (i.e., depression, anxiety,
body image, and self-esteem), participation, and
mortality rate.
Definitions of TTA and PFA were consistent with the
International Standards Organization (ISO) definitions
[51], and as such all levels of PFA, including toe amputa-
tion, were included, but ankle disarticulation (i.e., Syme’s
amputation) was excluded. Articles were included irre-
spective of the way the outcome of interest was oper-
ationally defined or the time point of measurement [44].
Search results were screened by one investigator based
on review of the title, abstract, or full-text article as ne-
cessary. Following screening, full-text articles were re-
trieved and independently reviewed by two investigators
to confirm inclusion. An additional opinion was sought
from a third investigator in cases of disagreement, and
discussion continued until consensus.
Quality appraisal/risk of bias in individual studies
The McMaster Critical Review Forms [52] were used to
assess methodological quality and identify sources of
bias. The appraisal tool was appropriate for use with a
wide variety of study designs [53] and included struc-
tured guidelines to reduce the likelihood of errors with
use [54]. Results from the quality appraisal were re-
ported in tabular format using Excel and included de-
tailed comments to support the checklist items [44].
Data extraction
Based on the Cochrane Consumers and Communication
Review Group’s data extraction template [55], sociode-
mographic, methodological, results, and quality appraisal
details were systematically recorded in an Excel spread-
sheet. Prior to implementation, the data extraction
spreadsheet was piloted and refined [44].
Included articles were independently appraised by two
reviewers. Data were extracted by a primary reviewer
and checked for accuracy and clarity by a second re-
viewer. As necessary, a third reviewer was called upon to
also appraise the article and contribute to the consensus
decision. Authors of the original research were con-
tacted for additional information or to clarify aspects of
the method where necessary. In making these contacts,
we emailed multiple authors from the same article and
followed up 2 weeks later if no response was received.
Where data for the same participants were reported
across multiple studies, subject numbers, demographics,
and outcomes were compared for discrepancies. If there
was uncertainty about the similarity of the study partici-
pants and results, authors of the original research were
contacted for clarification. Where the same subjects
were included in multiple studies, reference was made to
all the studies but data were treated as a single source.
Data summary and reporting
Review findings were reported as a narrative given that
the small number of studies were heterogeneous in
terms of their design, outcome measures, and subjects.
For some topics (i.e., mortality, ipsilateral reamputation)
the literature included a larger number of studies report-
ing the same outcome, at the same time points, in simi-
lar populations that allowed for meta-analysis. In these
cases, meta-analyses were conducted using proprietary
software (StatsDirect Ltd, Cheshire, UK) and a random-
effects model used given the assumption that treatment
effects varied across studies [56]. Where possible, pro-
portional meta-analyses were undertaken for each time
point to obtain point estimates and 95% confidence in-
tervals (95%CI) for the PFA and TTA cohorts. Similarly,
relative risk (RR) meta-analyses were undertaken to
compare the RR between PFA and TTA cohorts. Hetero-
geneity of results between studies was quantified using
the I2 statistic and explored using the findings of the risk
of bias assessment. Common issues with internal and
external validity (e.g., degree to which the PFA and TTA
cohorts are similar) were discussed with a specific focus
on limitations that lead to imprecision, indirectness, in-
consistency, and publication bias [57]. The extent to
which these issues impact the results was discussed and
lead to an understanding about which studies engender
the most confidence in the results and why. Findings
were first reported for a PFA sample, irrespective of the
level of amputation. Where possible, results were also
reported with a breakdown by level of PFA and com-
pared to the outcomes of people with TTA.
Results
Study selection
As summarized in the PRISMA flowchart, the search
yielded 4517 articles (Fig. 1). After duplicates were re-
moved, 2419 articles were vetted against the inclusion
criteria based on the title and abstract. A total of 452
full-text articles were reviewed. Of these, 25 articles met
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the inclusion criteria. The references of these 25 articles
were hand-searched resulting in an additional 4 articles
that met the inclusion criteria. Forward citation search-
ing identified additional five articles that met the inclu-
sion criteria. Of the 34 articles that met the inclusion
criteria, 5 were excluded because we were unable to con-
firm eligibility after efforts to contact authors (2 articles)
or obtain the necessary data (e.g., data reported as a
figure without supporting numerical data). In total, 29
articles were included in the review.
Study characteristics
The overwhelming majority of included studies reported
outcomes for populations in the USA with isolated stud-
ies in similarly developed countries [36, 38, 58–64].
Most of the included studies reported on mortality
[17, 18, 28, 59–63, 65–74] (Table 2). There were a small
number of investigations reporting outcomes related to
functional ability [35, 75], mobility [17, 33, 34, 76], QoL
[35, 36, 38], ipsilateral reamputation [27, 28, 58, 64–66, 70],
and wound healing and complications [18, 64, 74, 77]. No
studies that met the inclusion criteria reported on
pain, participation, or psychosocial outcomes.
Given the different topics included in the review, it
was perhaps not surprising that study designs varied
(Table 2). For example, most studies of mortality were
retrospective cohort studies of large national [28, 60, 66]
or state [71, 72] databases (Additional file 2: Table S6)
that resulted in very large participant numbers (n > 1000,
Table 3). By contrast, studies on QoL used case control
[35, 38] or cross-sectional [36] designs (Table 2) as
Fig. 1 PRISMA flowchart
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Table 2 Summary of study design and outcomes of included studies
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appropriate to the aims and recruited small samples (n <
30) when stratified by level of amputation (Table 3).
By virtue of the inclusion criteria, all studies reported
data for people with dysvascular PFA. Most studies re-
ported data for a single group that included people with
different levels of PFA [18, 27, 28, 35, 36, 38, 60–63, 65,
68, 70, 72, 73], often described by collective nouns such
as midfoot or minor amputation. Some data were re-
ported for discrete levels of PFA including toe [27, 28,
59, 64, 67, 69, 71], TMA [33–35, 58, 71, 74–76, 78], ray
[67], transtarsal [78], or partial/total calcanectomy [78].
A number of studies also included a cohort with
TTA [28, 33–36, 38, 61, 63, 69, 71, 72, 75, 76, 78].
Given the population of interest in this review (i.e.,
people with dysvascular PFA or TTA), it was not sur-
prising that studies included cohorts that were typically
older and male and had large proportions with diabetes
among other comorbidities (Table 2).
Quality appraisal/risk of bias
Based on the McMaster Critical Review Form, there were
a number of recurrent issues affecting both the internal
and external validity of studies included in the review.
While a detailed analysis of included studies has been pre-
sented as part of the appendices (Additional file 3) and
contextualized as part of the results narratives, a summary
of common issues has been included below.
Given the inclusion of people with dysvascular ampu-
tation, it was not surprising that a large proportion of
participants were older, male, and diabetic (Table 3). Un-
fortunately, there have been a disproportionate number
of studies that only included males [33, 34, 69, 70] or
people with diabetes [17, 18, 27, 34, 35, 38, 58, 62–64,
67, 69, 74]. While most studies reported these salient de-
tails, more detailed information about race, sociodemo-
graphic factors, or the presence of common
comorbidities were reported in an ad hoc way and as
such, it was not possible to make a detailed assessment
of the degree to which people included in research rep-
resented the broader population of people facing PFA or
TTA (Table 3).
There were a number of sources of bias common to
studies included in the review (Additional file 3). Con-
tamination and co-intervention were common, particu-
larly the use of treatments as an adjunct to surgery (e.g.,
vacuum-assisted closure therapy) or to manage comor-
bidities (e.g., renal impairment), which complicated stud-
ies of wound healing, reamputation, and mortality rates.
No studies justified the sample size (Additional file 3). In
comparison to studies of mortality or reamputation
rates, investigations of mobility, QoL, or functional abil-
ity tended to include small subject numbers (Additional
file 2: Table S3, S4, S5), which is not atypical of amputa-
tion research. While most studies used reliable and valid
outcome measures, studies of wound healing did not op-
erationally define what constituted a healed wound
(Additional file 2: Table S1).
Wound healing and complications
Four retrospective cohort studies met the inclusion cri-
teria [18, 64, 74, 77] and reported the proportion that
healed following PFA at discrete time points (Table 2).
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Studies included people with toe [64], TMA [74], or dif-
ferent levels of PFA in a single cohort [18, 77]. None
were designed to compare between different levels of
PFA (Additional file 2: Table S1). While one study [18]
included a PFA and TTA cohort, the rate of wound heal-
ing was not reported for the TTA cohort; instead it was
implied that 100% of people with TTA healed as none
progressed to transfemoral amputation [18] (Additional
file 2: Table S1).
While participants in these studies were fairly repre-
sentative in terms of their age and sex distribution, most
studies only included people with diabetes [18, 64, 74]
(Table 3). Detailed information about the presence of co-
morbidities (e.g., renal impairment) were reported in an
ad hoc fashion, which made it impossible to assess the
extent to which these comorbidities influenced healing
after amputation (Additional file 2: Table S1).
No studies operationally defined a healed wound
(Additional file 2: Table S1). Definitions such as “ad-
equately healed” [74] or “well-healed” [64] typify the im-
precision that likely contributed to the heterogeneity of
results between studies.
Although all studies described the proportion of the
sample that healed following PFA, there were few studies
reporting the outcome at any given time point. The pro-
portion of the sample that healed were reported for
3 weeks [64], 3 months [74, 77], and 1 year [18, 77] after
PFA. In one study [77], the proportion that healed at
1 year was calculated by combining the proportion of
the sample that healed at 3 months and those that
healed at some stage between 3 and 12 months.
Acknowledging the limited literature available, results
suggested that about 50% of PFAs healed at 3 months
(43–61%) [74, 77] and about 75% healed by 1 year (70–
88%) after amputation [18, 74]. There was considerable
uncertainty about these estimates given that they were
based on isolated studies, each with their own biases
(Additional file 3: Table S1). For example, the proportion
of the sample that healed at 3 and 12 months may be ar-
tificially low in the study by Stone et al. [74] given that
nearly all required a previous distal amputation and/or
debridement to control sepsis and were chronically un-
well as evidenced by the high proportion (26%) with
end-stage renal disease and contralateral lower limb am-
putation (16%).
Given such uncertainty in the evidence, the proportion
that healed at 3 weeks were not reported given that
those most likely to experience complications (e.g., those
with extensive cellulitis or ischemia requiring revascular-
ization) were excluded, therefore biasing the result to
the extent that outcomes were inconsistent with other
studies [64] (Additional file 3: Table S1).
Wound healing after PFA was complicated in a high
proportion of cases [18, 74]. For example, Evans et al.
[18] reported a perioperative complication rate of 42% in
a PFA cohort (time not defined), which reflected the
proportion of the sample that experienced dehiscence/
necrosis or ipsilateral reamputation (Additional file 2:
Table S1). The proportion of the sample that experi-
enced perioperative complications was reportedly lower
in the TTA cohort (28%), reflecting slightly different
complications including dehiscence/necrosis, bleeding,
and local wound revision. Although none operationally
defined the outcome, it was likely that the definition of a
complication varied across studies as did the use of par-
allel treatment (e.g., hyperbaric oxygen therapy) that
would also likely have affected the proportion that
healed after surgery (Additional file 3: Table S1).
Ipsilateral reamputation
Seven retrospective cohort studies met the inclusion cri-
teria, Table 2 [27, 28, 58, 64–66, 70]. Two [28, 66] used
the same population and were considered as a single
data source. While all studies described the proportion
of the sample that had undergone ipsilateral reamputa-
tion at a specific time point following PFA, the time
points were not the same across studies: 4 weeks [64],
6 months [70], 1 year [27, 28, 58, 65], 3 years [27, 70],
and 5 years [27, 65]. While there were enough studies to
calculate a point estimate and 95% confidence interval
for ipsilateral reamputation at 1 year, there were too few
studies at the other time points; hence, a narrative ap-
proach was used to describe proportionate ipsilateral
reamputation for 3 and 5 years after PFA.
Notwithstanding the limited literature available, results
indicate that 25% (95%CI, 16.47–34.64) of people re-
quired ipsilateral reamputation within 1 year of their
PFA (Fig. 2). Two studies reported data for multiple time
points [27, 65] highlighting that proportionate ipsilateral
reamputation increased over time (Additional file 2:
Table S2). By way of example, Izumi et al. [27] reported
that proportional ipsilateral reamputation increased
from 1 year (25%) to 3 years (39%) and 5 years (49%)
after PFA (Additional file 2: Table S2). While this in-
creasing proportion with ipsilateral reamputation over
time was consistent across studies, the rates at 3 years
(49%) [70] and 5 years (34%) [65] were very different,
highlighting the heterogeneity of results between studies
(Additional file 2: Table S2).
There was considerable uncertainty about propor-
tionate ipsilateral reamputation given the limited
number of studies and heterogeneity of the results
between studies. The representativeness of the cohorts
was of concern in more than half of the included
studies (Additional file 3: Table S2). For example,
Izumi et al. [27] likely under-represented the true
proportion that progressed to ipsilateral reamputation
given that the cohorts were relatively young (Table 3)
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where the long-term effects of diabetes are unlikely to
have impacted the outcome (Additional file 3: Table S2).
Issues with counting of reamputations were common
as exemplified by studies that did not count: subse-
quent amputations within a 2-week period of the
index (first ever) amputation [27], reamputation in
people who died within the first month [70], or cases
where more proximal amputation occurred within
the same admission [28] (Additional file 3: Table 2).
By contrast, other studies likely over-represented the
rate of proportional ipsilateral reamputation given
cohorts included older people [28, 66], many with
prior amputation [58], and serious comorbid condi-
tions such as coronary heart disease [70] (Additional
file 3: Table S2).
There were too few studies reporting data for people
with toe [27, 28, 64], ray [27], or TMA [58] at any time
point to produce meaningful estimates of proportionate
ipsilateral reamputation for different levels of PFA. Only
one of these studies, Izumi et al. [27] was designed to
compare between levels of PFA, and while we have raised
uncertainty about the representativeness of the propor-
tionate reamputation rate reported in this study, the com-
parison between different levels of PFA was fair because
the age bias affected the different PFA groups equally. As
such, the investigation by Izumi et al. [27] was best de-
signed to inform our understanding, highlighting that
there were no difference in the proportion of people who
progressed to ipsilateral reamputation at 1, 3, or 5 years
when stratified by toe, ray, or midfoot (i.e., TMA, Lisfranc,
Chopart) amputation (Additional file 2: Table S2).
Only one study [28] included a PFA and TTA cohort;
unfortunately, the study was not designed to compare
between levels of amputation and as such, only
descriptive data were available. Results suggest that there
was little difference between the proportion of people
with PFA (35%) and TTA (33%) that progressed to ipsi-
lateral reamputation within 1 year [28]. However, it was
likely that the true proportion of the PFA cohort that
progressed to ipsilateral reamputation was under-
estimated because people with toe amputation(s) were
excluded [28] (Additional file 2: Table S2).
Quality of life
Three studies reported QoL outcomes including two case
control studies [35, 38] and one cross-sectional study [36]
(Table 2). All studies used generic measures of QoL
including the Medical Outcome Study Short Form 36 (SF-
36) [36, 38] or the Sickness Impact Profile (SIP) [35].
Participants were broadly representative of the dysvas-
cular amputee population given that studies included
older adults with amputation due to peripheral vascular
disease following many years of living with diabetes
(Table 3). Different comorbidities were reported in all
three investigations to characterize the cohorts (Table 3).
The total number of subjects included in comparison
groups were small (n < 30), especially considering that
groups included varying levels of PFA (Table 3).
The two case control studies [35, 38] were designed to
compare QoL in subjects with amputation to those with-
out; these studies were not designed to compare QoL be-
tween groups with different levels of amputation
(Additional file 2: Table S3). One cross-sectional study
[36] was designed specifically to compare QoL in cohorts
with PFA and TTA and used a multivariate analysis of co-
variance (MANCOVA) to control for the confounding in-
fluence of age, time living with diabetes, and the presence
of diabetic complications (i.e., retinopathy, neuropathy,
Fig. 2 Proportional meta-analysis (random effects) for ipsilateral reamputation at 1 year after PFA
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nephropathy). While the study by Quigley et al. [36] was
limited by the small PFA group (n = 10) and included
people with different levels of PFA in that group, this in-
vestigation provided the best available evidence given that
it was designed to compare different levels of amputation
and controlled for covariates known to influence QoL
(Additional file 3: Table S3).
Overall, the very limited evidence suggests that QoL
was comparable in people with PFA and TTA. No stud-
ies have compared QoL in people with different levels of
PFA. Factors that significantly influence QoL included
advancing age, longer time living with diabetes, and the
presence of retinopathy [36]. Given that amputation at
either the PFA or TTA level did not have a significant
influence on QoL [36], it seems reasonable to suggest
that QoL is unlikely to differ between levels of PFA.
Functional ability
While two studies on functional ability met the inclu-
sion criteria [35, 75], one was incomprehensible [75]
(Additional file 3: Table S4). It seemed that the study
by Marzen-Groller et al. [75] modified the Functional
Independence Measure (FIM) to focus on seven activ-
ities relating to transfers, bed mobility, sit-to-stand
and distance walked, presumably each with their own
score. While three of these measures were reported in
the results, it was not clear whether the results
described a change score, an average score, or obser-
vations at one time point (Additional file 3: Table S4).
While these issues are by no means exhaustive, they
represent a critical limitation, that is, it was not clear
what was measured and as such, the study cannot
inform our understanding of functional ability after
PFA.
The second of these investigations [35] used the SIP to
compare functional ability and activity restriction in three
groups with diabetes and either PFA, TTA and/or transfe-
moral amputation, or no amputation [35]. The results in-
dicated that the total SIP scores were comparable in the
PFA and no amputation groups, despite the differences in
the physical dimension subscale scores (Additional file 2:
Table S4). This study was not designed to compare be-
tween levels of PFA or between cohorts with PFA and
TTA given the heterogeneous group of “major” amputa-
tions that included people with TTA and transfemoral am-
putation [35]. The ability to identify small differences
between these groups was limited because results were
highly variable and groups were not matched to control
for the confounding influence of systemic disease (e.g.,
duration of diabetes) nor were these differences controlled
for statistically (Additional file 3: Table S4). It was also dif-
ficult to generalize these results given that demographic
and health characteristics were not reported by amputa-
tion level (Additional file 3: Table S4). Given these
limitations, it was not possible to vest confidence in these
results without other studies to corroborate these
findings.
Mobility
Four cohort studies on mobility met the inclusion cri-
teria, Table 2 [17, 33, 34, 76]. Given that the same partic-
ipants were included in two of the studies [33, 34] and
that a subset of this sample was used in the third study
[76], these studies were considered as a single source
(Additional file 2: Table S5).
There were substantive methodological concerns with
the one study that used the Volpicelli ambulatory scale
[17]. The Volpicelli ambulatory scale was inappropriate
for use in this unilateral population because it was de-
signed for use in people with bilateral limb loss [79]. It
is likely that some participants with unilateral amputa-
tion experienced a ceiling effect with the use of this
measure (Additional file 3: Table S5). The results were
reported using means and standard deviations, which
was also inappropriate given the measure’s ordinal scale
and rendered the mutually exclusive categories of the ori-
ginal measure meaningless (Additional file 3: Table S5).
The small differences reported between groups are likely
to be spurious, and the results should be interpreted with
caution (Additional file 3: Table S5). Due to these con-
cerns, the study was unsuitable to inform our understand-
ing of mobility.
Participants in the remaining three studies [33, 34, 76]
were broadly representative of the dysvascular ampu-
tee population as evidenced by their average age,
cause of amputation, and presence of common co-
morbidities (Table 3). However, all participants were
male and a large proportion (>85%) had diabetes
[33, 34, 76]. These studies included cohorts with TTA
and TMA [33, 34, 76].
The Locomotor Capabilities Index-5 (LCI-5) was used to
assess mobility over time (i.e., premorbid mobility recalled
at 6 weeks post-amputation and mobility at 4, 6, and
12 months post-amputation) and between cohorts with
TMA, TTA, and transfemoral amputation [33, 34, 76].
While these studies [33, 34, 76] were generally methodo-
logically strong, recall bias may have influenced the ability
of participants to rate their premorbid mobility 6 weeks
after amputation (Additional file 3: Table S5). However, this
issue does not affect the conclusion that from 6 weeks
post-amputation, mobility continued to improve at each
successive time point until the last measure at 12 months
for both the TMA and TTA cohorts [34]. While these
studies were not designed to compare mobility at 6 weeks
or 4 months post-amputation, descriptive data suggests
that mobility was better for the TMA cohort than for the
TTA cohort at these time points [34] (Additional file 2:
Table 5). However, at 12 months post-amputation self-
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reported mobility seemed to be very similar for people with
TMA and TTA [33, 34] (Additional file 2: Table S5). At the
12-month follow-up, only one-third of people with TMA
or TTA returned to their premorbid level of mobility [33].
Mortality
Of the 22 articles that reported mortality outcomes
and met the inclusion criteria, we were unable to ob-
tain complete data [80, 81] or verify critical details to
confirm inclusion [82, 83] from the authors of four
articles; hence, 18 studies were reviewed (Additional
file 2: Table S6). While most studies were retrospect-
ive cohort studies [17, 18, 28, 59–61, 65–74], there
was one cross-sectional [62] and one case control
[63] study (Table 2). Two studies [28, 66] examined
the same population and were therefore treated as a
single data source. A number of studies included very
large samples [28, 60, 62, 65, 66, 68, 71, 72] typical of
national- or state-based population studies, which
added considerably to the power with which conclu-
sions about mortality could be made (Table 2).
While our protocol specified inclusion of studies
reporting a mortality rate, the term was imprecisely used
among studies. Only one study [63] reported a true mor-
tality rate (i.e., age-standardized all-cause mortality rate
per 1000 person-years). However, all included studies re-
ported all-cause proportionate mortality (or survival
from which mortality was calculated) and included add-
itional information about the time point at which it was
measured (Additional file 2: Table S6).
Proportionate mortality was determined either by
counting the proportion of the sample that died over time
[6, 18, 28, 59, 61, 68–70] or by using a Kaplan-Meier
analysis [17, 62, 63, 65, 67, 71, 73] (Additional file 2:
Table S6). In one study, it was not clear which of
these two approaches was used to generate the pro-
portionate mortality reported [72] (Additional file 2:
Table S6). Most commonly, proportionate mortality
was reported for a perioperative period of 30 days
[59–61, 71–73] or for 1 year [17, 28, 60, 61, 63, 65,
68, 72–74], 3 years [17, 65, 69, 70, 74], or 5 years
[63, 65, 67–69, 71–74] after amputation, acknowledg-
ing that not all studies reported proportionate mortal-
ity at each time point. There were isolated data for
other time points including 3, 6, and 10 months or
2 years post-amputation [18, 62, 63, 67, 74].
A number of studies reported proportionate mortal-
ity for a PFA group without breakdown by level of
amputation [18, 60–63, 68, 70, 73]. A few studies in-
cluded more refined data for cohorts that included
multiple levels of PFA (e.g., toe/TMA) [28, 65, 72] or
discrete levels including toe(s) [28, 59, 67, 69, 71], ray
[67], TMA [17, 71, 74], Chopart [17], or calcanectomy
[84]. A number of these studies also included a TTA
cohort [28, 61, 63, 69, 71, 72, 84].
Given the number of studies that reported the same out-
come at standard time points in similar cohorts with
dysvascular PFA, we conducted a series of proportional
meta-analyses to integrate the results from these
independent studies and provide point estimates of pro-
portionate mortality. All studies were included in the
meta-analyses in keeping with the view that there is a
common truth behind similar studies and that preserving
information about the heterogeneity of results between
studies is important to explain underlying causes of vari-
ation and uncertainty in the point estimates reported [85].
Following PFA, proportionate mortality increased from
30 days (2.8%, 95%CI 2.2–3.6) to 1 year (17.3%, 95%CI
14.6–20.2), 3 years (30.6%, 95%CI 23.0–38.7), and 5 years
(41.2%, 95%CI 32.6–50.1) (Fig. 3). There was consider-
able heterogeneity in the results between studies (I2 >
70%, p < 0.01) and while this did not detract from the
precision of the point estimate at 30 days, estimates of
proportionate morality became less precise over time
(Fig. 3). Fortunately, studies that most contributed to the
heterogeneity received less weighting in the random-
effects meta-analysis and thereby had the least influence
on the point estimates.
Given that measures of proportionate mortality do not
control for variations in the sample characteristics (e.g.,
older age), this was a notable source of variation in the
results (Additional file 2: Table S6). For example, the
study by Kristensen et al. [61] included a sample that
was old (75.8 ± 11.4 years), chronically unwell (20% had
4–5 comorbidities, 10% had American Society of Anes-
thesiologists (ASA) scores ≥4 indicative of a systemic
disease that is life threatening or people who are not ex-
pected to survive), and included a large proportion
(18%) with prior amputation (Additional file 2: Table S6).
As such, it was not surprising that proportionate mortality
was multiple times greater compared to studies with more
representative samples (Fig. 3). Proportionate mortality
was also greater than might be expected in other
studies where the samples were similarly unrepresen-
tative [17, 70, 73, 74]. By contrast, proportionate mor-
tality was low in two studies [67, 68] given that only
those with index amputation were included and par-
ticipants were relatively young where the serious com-
plications of diabetes might not yet have increased the risk
of mortality (Additional file 3: Table S6).
Aside from sample characteristics, heterogeneity of the
results between studies was also due to variation in the
usual care provided (Additional file 3: Table S6). Varia-
tions in care are not surprising given that most studies
were retrospective reviews of national- or state-wide
datasets that included outcomes from multiple health-
care providers over many years. While issues with co-
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intervention and contamination were typically not ad-
dressed (Additional file 3: Table S6), some investigations
described aspects of care that likely vary across studies.
For example, Evans et al. [18] described routine tendon
rebalancing, hyperbaric oxygen therapy (24% of the sam-
ple used this treatment), and multiple debridement pro-
cedures (average two per person) following PFA
(Additional file 3: Table S6). In other studies, revascular-
ization procedures either prior to, or in parallel with,
amputation were reported [59, 65, 74], as were lengthy
periods of non-weight bearing [74] and the use of
vacuum-assisted closure therapy [59, 65] (Additional file
3: Table S6). Considering that many people facing PFA
also have serious comorbidities (e.g., renal insufficiency,
congestive heart failure), treatments in addition to those
directly related to the amputation are likely to have in-
fluenced mortality.
When considered with respect to level of PFA, there
were too few studies (≤3) reporting proportionate mor-
tality at any time point to warrant meta-analysis, par-
ticularly given that these studies [17, 67, 74] have
already been shown to influence the heterogeneity of re-
sults between studies and, without other investigations
with which to compare the outcome, it was difficult to
vest confidence in the result of the meta-analysis of iso-
lated studies. Of the studies that reported proportionate
mortality for different levels of PFA [17, 28, 67, 71], only
one was designed to compare between levels [67] and, as
such, this study was best designed to inform our under-
standing. Izumi et al. [67] found no statistically signifi-
cant difference in proportionate mortality between
groups with toe, metatarsal ray resection, or midfoot am-
putation (i.e., cohort included TMA, Lisfranc and Cho-
part amputations) at 10 months (toe 6.6%, ray 4.4%,
midfoot 10.5%) and 5 years (toe 26.2%, ray 15.8%, mid-
foot 21.0%) (Additional file 2: Table S6).
Following TTA, proportionate mortality increased from
30 days (7.8%, 95%CI 5.2–10.8) to 1 year (34.2%, 95%CI
22.5–46.9) and 5 years (54.6%, 95%CI 42.9–66.1). There
were insufficient studies reporting 3-year proportionate
mortality to warrant a meta-analysis, particularly given the
small number of subjects in these studies [17, 69] (Add-
itional file 2: Table S6).
In comparison to people with PFA, those with TTA
had a significantly greater RR of dying at 30 days (RR
2.6, 95%CI 1.6–4.1, p < 0.001), 1 year (RR 1.5, 95%CI
1.4–1.6, p < 0.001), and 5 years (RR 1.3, 95%CI 1.2–1.5,
p < 0.001, Fig. 4). It is important to note that the RR of
mortality was disproportionately high in the periopera-
tive period compared to 1 and 5 years after amputation
(Fig. 4). Two studies [71, 72] that most influenced the
RR meta-analysis at 30 days post-amputation both oper-
ationally defined the highest amputation level as the
index amputation (Additional file 3: Table S6). If we
Fig. 3 Proportional meta-analysis (random effects) for mortality at
30 days, 1, 3, and 5 years after PFA
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assume that the 15% of people who required multiple
amputations in the same admission [71] are also those
with the worst health and therefore at greatest risk of
dying, and we categorize them by the highest level of
amputation, it artificially inflates the RR of perioperative
mortality toward TTA (Additional file 3: Table S6).
While the RR of perioperative mortality may be artifi-
cially inflated toward those requiring TTA, comorbid-
specific Kaplan-Meier analyses [71] highlighted that the
very high mortality in the first year after amputation were
associated with renal disease, congestive heart failure, and
cerebrovascular disease (Additional file 3: Table S6). Un-
fortunately, demographic and comorbid conditions were
not reported by cohorts with PFA and TTA [71], which
made it impossible to assess the extent to which the pres-
ence of these conditions differed between cohorts and
contributed to the higher RR of perioperative mortality for
people with TTA compared to those with PFA (Additional
file 3: Table S6).
Given an understanding of the leading causes of
death after amputation [63, 71], the increased RR of
dying for those with TTA may not be due to the am-
putation per se given that, in all likelihood, people
with TTA have more advanced systemic disease that
both increased the RR of dying and necessitated more
proximal amputation.
The degree to which heterogeneity of the results varied
between studies depended on the time point (Fig. 4). Of
particular interest was the heterogeneity between results for
30 days post-amputation (I2 = 73.2%, p = 0.024, Fig. 4) given
the similarity of two of these studies [71, 72]; both include
very similar populations based on the demographic and co-
morbid conditions reported (Table 3) and operationally de-
fined the index amputation as the highest amputation level
(Additional file 3: Table S6). Unfortunately, one of these
studies [71] did not report demographic and comorbid con-
ditions by cohorts with PFA and TTA, making it impos-
sible to assess the extent to which the sample
characteristics influenced the heterogeneity of results
between studies (Additional file 2: Table S6). While
issues with the representativeness of the sample de-
scribed by Kristensen et al. [61] have already been
discussed, these were of little consequence given that
the other studies reporting 30-day proportionate mor-
tality [71, 72] were less heterogeneous and thereby
dominated the point estimate (Fig. 4).
Discussion
The purpose of the review was to describe a comprehen-
sive range of outcomes following dysvascular PFA and to
compare these between levels of PFA and TTA.
Aside from mortality, there was limited evidence re-
garding outcomes of dysvascular PFA, particularly how
outcomes differed between levels of PFA and TTA. The
available evidence suggests that
 Wound healing and complications: about 50% of
PFAs healed at 3 months and about 75% healed by
1 year. Complications such as dehiscence and
necrosis affected a large proportion of people
Fig. 4 Relative risk meta-analysis (random effects) comparing mortality
at 30 days, 1 and 5 years after PFA and TTA
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following PFA, and these complications may affect a
smaller proportion following TTA.
 Ipsilateral reamputation: about 25% of people with
PFA required an ipsilateral reamputation within
1 year. While this proportion increased over time,
there was uncertainty about the rate of ipsilateral
reamputation at later time points. Given the limited
evidence, there was also uncertainty that the rates of
ipsilateral reamputation were comparable between
levels of PFA and TTA.
 QoL: QoL may be similar in people with PFA and
TTA. While no studies have compared QoL
between levels of PFA, research suggests that older
age, time with diabetes, and the presence of diabetic
complications had a significant influence on QoL,
where amputation level did not.
 Functional ability: there was uncertainty about the
outcomes given just one study suggests functional
ability may be similar in people with PFA and no
amputation. No studies compared functional ability
between levels of PFA and TTA.
 Mobility: for most people, mobility declined
following PFA. Only one-third of people with TMA
returned to their premorbid mobility level 1 year
after amputation. Mobility seemed comparable in
people with TMA and TTA; acknowledging that in
the first months following amputation, mobility may
be better for people with TMA. No studies have
compared mobility between levels of PFA or re-
ported mobility outcomes for different levels of PFA
(only TMA).
 Mortality: about 17% of people died within 1 year of
their PFA, that proportion increased over time such
that by 5 years about 40% of people died. While
there was uncertainty that mortality outcomes were
the same in people with different levels of PFA,
people with TTA had a greater risk of dying. The
increased risk of death in people following TTA may
not be due to the amputation per se, but may simply
relect more advanced systemic disease that also
required more proximal amputation.
While no studies reporting participation, pain or psy-
chosocial outcomes included discrete groups with PFA,
and therefore did not meet the inclusion criteria, there
exists a broader body of literature that must be acknowl-
edged. Our systematic search of the literature identified
investigations of psychosocial outcomes that included
cohorts with different levels and causes of lower limb
amputation focusing on body image [86–88], sexuality
[89, 90], depression [91–93], psychological adjustment to
amputation [94–98], and life goal adjustment [99]. A
number of studies also described links between psycho-
logical features such as stress or depression and phantom
limb pain [100–105]. Similarly, studies reporting participa-
tion outcomes in people with limb loss have investigated
return to work [106], negotiation of environmental bar-
riers [107], social activity participation [108, 109], and par-
ticipation and autonomy [110].
Given this understanding, investigations that stratify
by level of amputation are needed to more fully under-
stand the effect of PFA and how outcomes vary between
levels of PFA and TTA. Such studies could easily address
many of the methodological issues highlighted in this re-
view including operationally defining the outcome of
interest (e.g., using a standardized wound classification
system to measure healing), standardizing time points
for measurement (e.g., perioperative mortality might al-
ways be 30 days after amputation), and stratification by
level of amputation—even as a secondary outcome. As
the body of literature grows, these small changes to
method design will facilitate future synthesis of the
evidence.
Application of evidence to the development of shared
decision-making resources
Critical appraisal and synthesis of the outcomes of PFA
and how these compared between levels of PFA and
TTA, provides a well-evidenced foundation for building
shared decision-making resources. For example, point
estimates for mortality at 1, 3, and 5 years after PFA re-
ported in this review can be incorporated into a patient
decision aid and discussion guide to help patients under-
stand their risk of dying and inform difficult conversa-
tions at the point of amputation surgery. In this way,
patients and doctors can engage in these difficult con-
versations with an informed understanding of the
current research evidence, even acknowledging the un-
certainty that exists in many outcomes. Allied health
practitioners can also use evidence reported in this re-
view to help inform discussions about the likely out-
comes following PFA.
Limitations
Differences between protocol and review
While developing the protocol for this review, we specified
a number of outcomes of interest with reference to a rate
(e.g., mortality rate). We had not appreciated that the term
rate had different meanings in the literature. In an epidemi-
ology context, the term rate has a very specific meaning: a
mortality rate describes the number of people that die dur-
ing a specific time period divided by the number of people
at-risk of dying in that time period [111]. Given that the
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number of people at-risk changes over time (i.e., as people
die they are no longer at-risk of dying), the mortality rate is
often expressed per 1000 person-years (e.g., 50 deaths per
1000 person-years). Only one study [63] reported a true
mortality rate (i.e., age-standardized all-cause mortality rate
per 1000 person-years). All studies included in the review
reported a proportion of the sample that died. Measures of
proportion do not include information about time and, in
this way, they differ from rates. Obviously, if the duration of
a study was long enough, 100% of people would die. With-
out information about time, measures of proportionate
mortality are not terribly useful to inform patients about
their likelihood of dying. Ideally, measures of proportionate
mortality should define the time point at which the out-
come was measured (e.g., 50% of people died within 5 years
of their amputation). Given this understanding, we included
studies that reported a proportional mortality/wound heal-
ing/ipsilateral reamputation as long as a time point was
specified and as such, it was redundant to report the out-
come time to ipsilateral reamputation because the time
point was now inherent to the definition of the ipsilateral
reamputation. We hope to have been transparent in de-
scribing this change to the protocol and believe that it
would have been disingenuous to exclude these studies
based on the operational definition of the outcome, particu-
larly given their importance to conversations about limb
loss.
We reported outcomes related to wound healing after
amputation rather than wound failure given that wound
healing was the term used in the literature.
We also expanded the protocol to undertake a series of
meta-analyses to produce point estimates for proportional
mortality and ipsilateral reamputation as well as estimate
the RR of mortality for those with TTA compared to PFA.
At the point of designing the protocol, we had not antici-
pated a sufficiently large body of literature reporting the
same outcomes at the same time points on any topic that
make meta-analyses feasible. We believe that reporting
these meta-analyses as part of the narrative review engen-
ders greater confidence in our summary of the propor-
tional mortality and ipsilateral reamputation results.
Other limitations
Given the large number of outcomes included in this
review, we have deliberately kept the results narratives
very tight by using illustrative examples to showcase
the risk of bias and the impact on the results. Detailed
results of the risk of bias assessment have been in-
cluded as Additional file 3, rather than in the body of
the work, given the sheer size of the tables. We hope
that readers can appreciate the rationale for this ap-
proach and our efforts to report all our data in its en-
tirety for those wanting this level of detail.
During the review process, we contacted authors from
11 articles. Authors of nine articles responded, which
allowed us to clarify important details necessary to de-
termine eligibility or obtain additional data. As such,
only two articles were excluded because we could not
establish contact with authors.
Some may be critical that our literature search was
limited to the last 15 years, particularly given that no ar-
ticles on pain, participation, or psychosocial outcomes
included groups with PFA and therefore did not meet
the inclusion criteria. Our intention was to synthesize
current research evidence given that changes in treat-
ment practices have dramatically influenced the types of
amputations being performed, cointerventions that often
occur in parallel (e.g., revascularization), and the way we
treat conditions such as pain or depression. As such, we
felt that older literature offered little to inform our un-
derstanding of the outcomes of contemporary practice.
The quality of reporting and research methods varied
markedly across investigations, and it was often difficult
to draw meaningful conclusions as part of the narrative
review. This is not atypical of emerging areas of research.
Given that people still need to make informed decisions
about their healthcare in lieu of rigorous research evi-
dence, we hope to have guided the reader to an under-
standing of the best available evidence by discussing
uncertainty and issues that most inform our view.
Some may be critical of our inclusion of all studies in
the meta-analysis in keeping with the view that there is a
common truth behind similar studies and that preserv-
ing information about the heterogeneity of results be-
tween studies is important to explain underlying causes
of variation and uncertainty in the point estimates re-
ported [85]. By exploring the heterogeneity of results
using insights gleaned from our risk of bias assessment,
we hope to have engendered confidence in the findings
reported.
Some readers may also be critical of our decision to omit
summary statistics describing the number of studies or par-
ticipants from the discussion. While this may be typical,
and indeed appropriate in well-developed bodies of litera-
ture, we felt it was misleading to further contextualize our
discussion points based on the number of studies or partici-
pants. For example, of the four cohort studies reporting
mobility outcomes [17, 33, 34, 76], we had significant con-
cerns about use of the Volpicelli ambulatory scale [17] be-
cause it was designed for the use in people with bilateral
amputation and inappropriately used in a unilateral popula-
tion where some participants experience a ceiling effect.
While we have explained why the study was unsuitable to
inform our understanding as part of the results narrative,
we are concerned that this understanding is lost when the
total number of articles or participants are included as part
of a summary of the key findings.
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Conclusions
This review of a comprehensive range of outcomes follow-
ing dysvascular PFA and how these compare between levels
of PFA and TTA highlights that evidence was limited. Not-
withstanding the uncertainty that comes from small bodies
of literature where the risk of bias is high, the available evi-
dence suggests that a large proportion of people with dys-
vascular PFA will wait many months for wound healing
and experience complications such as dehiscence or ream-
putation on the same limb. A large proportion of people
will die within a few years following dysvascular PFA. While
the risk of dying was higher for people with TTA, this may
be due to advanced systemic disease that makes TTA a
more appropriate amputation surgery. While outcomes
such as mobility and QoL appear to be similar in people
with PFA and TTA, these inferences are based on isolated
studies involving small subject numbers and as such, fur-
ther research is needed to be confident in these findings.
No studies that reported on pain, participation, or psycho-
social outcomes included discrete groups with PFA and as
such, our understanding of the impact of PFA must be in-
formed by the broader body of literature describing these
outcomes for heterogeneous groups with lower limb
amputation.
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